The power of MSCs to treat pain at its source

Regeneus has two lead platform technologies Progenza™ and Sygenus. Our technologies are supported by robust intellectual property and manufacturing capabilities.

We apply the technology to multiple indications. Our current therapeutic areas include knee osteoarthritis, neuropathic pain and skin inflammation.


Progenza™ is a cryopreserved multi-synergistic therapy targeting pain and inflammation. Regeneus has patented techniques and high-quality testing to ensure the production of millions of Progenza™ doses from a single donor (allogeneic).

Learn more about Progenza™


A topical Secretome product. Sygenus contains the bioactive molecules from the Secretome to reduce pain and inflammation while accelerating tissue healing and repair. The safety and tolerability of Sygenus have been confirmed in human pilot studies.

Learn more about Sygenus